Jenburkt Pharmaceuticals (524731) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
6 Aug, 2026Executive summary
Standalone unaudited financial results for the quarter ended 30th June 2026 were reviewed and approved by the Board on 6th August 2026.
The company operates exclusively in the pharmaceuticals segment.
Financial highlights
Revenue from operations for Q1 FY27 was ₹3,551.20 lakhs, nearly flat year-over-year (₹3,552.68 lakhs in Q1 FY26).
Total income for the quarter was ₹3,702.52 lakhs, compared to ₹3,758.39 lakhs in Q1 FY26.
Profit before tax for Q1 FY27 was ₹676.91 lakhs, down from ₹1,018.20 lakhs in Q1 FY26.
Profit after tax for Q1 FY27 was ₹588.56 lakhs, compared to ₹779.18 lakhs in Q1 FY26.
Earnings per share (EPS) for Q1 FY27 stood at ₹13.34, versus ₹17.66 in Q1 FY26.
Outlook and guidance
No explicit forward-looking guidance or outlook was provided.
Latest events from Jenburkt Pharmaceuticals
- Revenue and profit rose, dividend declared, and audit opinion unmodified for FY 2025-26.524731
Q4 25/26 - Q3 FY26 saw higher revenue but lower profit after tax and EPS, with added labour cost provisions.524731Q3 25/26
- Revenue and net profit rose year-over-year, with EPS at ₹23.03 and strong cash flow.524731Q2 25/26
- Revenue and profit after tax rose year-over-year, with EPS reaching ₹17.66.524731Q1 25/26
- Strong revenue and profit growth reported for Q2 FY25, with higher EPS and cash flow.524731Q2 24/25
- Q1 FY25 saw higher revenue, profit, and EPS, with continued focus on pharmaceuticals.524731Q1 24/25
- Q3 FY25 saw higher revenue, profit, and EPS, with clean auditor review and pharma focus.524731Q3 24/25
- FY25 net profit rose 23% to ₹3,206 lakh; ₹18/share dividend declared.524731Q4 24/25